Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.

ABSTRACT:

Background

The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker.

Methods

We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson's disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson's disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers.

Results

In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson's disease pa

SUBMITTER: Mollenhauer B 

PROVIDER: S-EPMC8017468 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature